{"id":253567,"date":"2026-09-17T15:29:50","date_gmt":"2026-09-17T09:59:50","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=253567"},"modified":"2026-09-17T15:29:50","modified_gmt":"2026-09-17T09:59:50","slug":"pathology-lab-stock-rises-38-percent-in-1-year","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pathology-lab-stock-rises-38-percent-in-1-year\/","title":{"rendered":"This Pathology Lab Stock Rises 38% in 1 Year: Bonus Shares, a Debt-Free Parent and a Shrinking Promoter Stake"},"content":{"rendered":"

Thyrocare: CMP Rs 557.55 on 17 Sep 2026, up 2.99%. 1-year return 38.42%. 52W range Rs 342.55 to Rs 662. Market cap Rs 8,589 Cr. Q1 FY27 PAT Rs 51.33 Cr.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Thyrocare Technologies is the pathology lab stock that rose approximately 38% between 17 September 2025 and 17 September 2026, from a bonus-adjusted Rs 402.80 to Rs 557.55. The gain came from an earnings recovery, a first-ever 2:1 bonus issue and a parent group that cleared its debt. The share is still around 16% below its Rs 662 peak of 12 August 2026.<\/p>\n<\/div>\n

This pathology lab stock rose approximately 38% over the past year on a screen of NSE small-cap stocks ranked by 1-year return, dated 17 September 2026. The bonus-adjusted close was Rs 402.80 on 17 September 2025 against Rs 557.55 on 17 September 2026, up 2.99% on the day.<\/p>\n

The company is Thyrocare Technologies Ltd<\/a><\/strong> (NSE: THYROCARE), a diagnostics business built on centralised testing and a large franchisee network. The Thyrocare share price story has two halves: an earnings recovery that lifted FY26 profit by roughly 79%, and parent API Holdings using this holding to repay its own borrowings, cutting promoter ownership from 71.06% to 51.02% in under a year.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n